biomarkers in prostate cancer, part ii prostate cancer symposium september 17, 2011
DESCRIPTION
Biomarkers in Prostate Cancer, part II Prostate Cancer Symposium September 17, 2011. Clara Hwang, MD Internal Medicine Hematology/Oncology. Biomarkers – the holy grail of personalized medicine?. - PowerPoint PPT PresentationTRANSCRIPT
Biomarkers in Prostate Cancer, part IIBiomarkers in Prostate Cancer, part IIProstate Cancer SymposiumProstate Cancer Symposium
September 17, 2011September 17, 2011
Clara Hwang, MDClara Hwang, MD
Internal MedicineInternal Medicine
Hematology/OncologyHematology/Oncology
Biomarkers – the holy grail of Biomarkers – the holy grail of personalized medicine?personalized medicine?
• Advances in technology (genomics, proteomics) Advances in technology (genomics, proteomics) have offered the promise of personalized have offered the promise of personalized medicine, where therapies and medical decision medicine, where therapies and medical decision making can be finely tailored to patients.making can be finely tailored to patients.
• Potential benefits include improving clinical Potential benefits include improving clinical efficacy and decreasing toxicity by better efficacy and decreasing toxicity by better treatment selection and patient selection.treatment selection and patient selection.
Phases of biomarker developmentPhases of biomarker development
• Discovery – ~Phase IDiscovery – ~Phase I• Identify relationship between molecular marker and clinical Identify relationship between molecular marker and clinical
outcome; ideally identify causal relationshipoutcome; ideally identify causal relationship
• Analytic Validation – ~Phase IIAnalytic Validation – ~Phase II• Develop lab SOP/QC, reliability in clinical samplesDevelop lab SOP/QC, reliability in clinical samples• Selectivity, sensitivity, CR, precision, accuracy Selectivity, sensitivity, CR, precision, accuracy
• Clinical Qualification – ~Phase IIIClinical Qualification – ~Phase III• Confirm correlation with clinical outcomesConfirm correlation with clinical outcomes
• Clinical implementation - ~Phase IVClinical implementation - ~Phase IV
Clinical utility of biomarkers Clinical utility of biomarkers in prostate cancer in prostate cancer
Clinical scenario Example
Detection PSA for early diagnosis
Prognosis Gleason score
Prediction ER positivity and hormone Rx;none exist for prostate cancer
Pharmacodynamic Testosterone for GnRH agonist
Clinical surrogate PSA decline as tumor marker
Prostate cancer clinical statesProstate cancer clinical statesand treatment decisionsand treatment decisions
Localized disease
Metastatic disease
Should I start treatment? (Prognostic biomarker)
Which treatment should I use? (Predictive biomarker)
Is my treatment working? (Pharmacodynamic biomarker)
Is my treatment helping the patient? (Surrogate biomarker)
Current landscape of treatments for castrate-Current landscape of treatments for castrate-resistant metastatic prostate cancerresistant metastatic prostate cancer
• Minimally symptomatic – sipuleucel-TMinimally symptomatic – sipuleucel-T• 11stst line – docetaxel line – docetaxel• 22ndnd line – line –
• Abiraterone Abiraterone • Cabazitaxel Cabazitaxel
• 33rdrd line – mitoxantrone line – mitoxantrone
Biomarkers to assess response to Biomarkers to assess response to systemic therapysystemic therapy
• Limitations of systemic therapy – all Limitations of systemic therapy – all patients will ultimately progresspatients will ultimately progress
• Some patients will not have an initial Some patients will not have an initial response to therapyresponse to therapy
• Are there predictive or surrogate Are there predictive or surrogate biomarkers to guide treatment decisions?biomarkers to guide treatment decisions?
Response markers in prostate cancerResponse markers in prostate cancer
• In current clinical useIn current clinical use• PSAPSA• Pain Pain • Bone scanBone scan• CT scan/ MRI scan (RECIST)CT scan/ MRI scan (RECIST)
• ExperimentalExperimental• Circulating tumor cellsCirculating tumor cells
The difficulty of assessing response to The difficulty of assessing response to therapy in mCRPCtherapy in mCRPC
““PCWG2 advises that, in the absence of PCWG2 advises that, in the absence of clinically compelling indicators of disease clinically compelling indicators of disease progression, early changes (within 12 progression, early changes (within 12 weeks) in indicators such as serum PSA, weeks) in indicators such as serum PSA, patient-reported pain, and radionuclide patient-reported pain, and radionuclide bone scan be ignored.”bone scan be ignored.”
Scher et al JCO 2008 v26(7) p 1148
Clinical examples of using PSA as Clinical examples of using PSA as biomarker for treatment responsebiomarker for treatment response
• PSA responses from PSA responses from three patients started on three patients started on chemotherapy with CRPCchemotherapy with CRPC
• On occasion, PSA will On occasion, PSA will rise prior to falling (PSA rise prior to falling (PSA flare response)flare response)
PSA response as surrogate markerPSA response as surrogate marker
• Retrospective analysis of patients on Ph III Retrospective analysis of patients on Ph III comparision of D+E vs M+P (S9916)comparision of D+E vs M+P (S9916)
• 3 month 30% PSA decline defined to have 3 month 30% PSA decline defined to have occurred if lowest PSA within first three occurred if lowest PSA within first three months <=50% of baseline valuemonths <=50% of baseline value
• By this definition – occurred in 76% in D+E By this definition – occurred in 76% in D+E arm vs 40% in M+Parm vs 40% in M+P
Petrylak 2006 JNCI 98:516
PSA decline as surrogate marker in PSA decline as surrogate marker in S9916S9916
Original figure of MP vs. DE compared to OS curve of patients with PSA decrease >=30% in 3 mo vs < 30%
Petrylak 2006 JNCI 98:516
Circulating tumor cells (CTC)Circulating tumor cells (CTC)
• In patients with solid tumors, circulating In patients with solid tumors, circulating tumor cells can be detected in circulationtumor cells can be detected in circulation
• Rare (1 in 10Rare (1 in 1099 nucleated cells) nucleated cells)
• Provide a source of tumor cells for Provide a source of tumor cells for molecular profilingmolecular profiling
• For Cellsearch assay, cutoff for favorable For Cellsearch assay, cutoff for favorable vs unfavorable is 5 CTC per 7.5 mL bloodvs unfavorable is 5 CTC per 7.5 mL blood
CTC detection with CellSearchCTC detection with CellSearch
Only FDA approved, analytically validated CTC assay
Baseline CTC is prognostic in mCRPC Baseline CTC is prognostic in mCRPC patients treated with cytotoxic therapypatients treated with cytotoxic therapy
de Bono J S et al. Clin Cancer Res 2008;14:6302-6309
Conversion of CTC as predictor of Conversion of CTC as predictor of overall survival overall survival
de Bono J S et al. Clin Cancer Res 2008;14:6302-6309
CTC enumeration vs PSA decline as CTC enumeration vs PSA decline as predictor of overall survivalpredictor of overall survival
Clinical utility of biomarkers Clinical utility of biomarkers in prostate cancer, revisitedin prostate cancer, revisited
Clinical scenario Example
Detection PSA for early diagnosis
Prognosis Gleason score
Prediction ER positivity and hormone Rx;none exist for prostate cancer
Pharmacodynamic Testosterone for GnRH agonist
Clinical surrogate PSA decline as tumor marker
Markers that correlate with docetaxel-Markers that correlate with docetaxel-sensitivitysensitivity
underexpressed in sensitive cell lines overexpressed in sensitive cell lines
Effect of SKP2 knockdown on docetaxel response
docetaxel concentration (log scale)
1 10 100
Ce
ll v
iab
ilit
y,
% b
as
eli
ne
40
60
80
100
Actin
SKP2
si-S
KP2si
-Non
Targ
et
0.0
0.2
0.4
0.6
0.8
1.0
LNCAP
Rel
ativ
e Q
uan
tita
tio
n
si-SKP2
si-nontarget
Causal relationship between SKP2 and Causal relationship between SKP2 and docetaxel responsedocetaxel response
ConclusionsConclusions
• PSA decline may be used as a surrogate PSA decline may be used as a surrogate marker for response (after 12 weeks)marker for response (after 12 weeks)
• Baseline levels of CTC are prognostic for Baseline levels of CTC are prognostic for OSOS
• Conversion of CTC correlates with OS but Conversion of CTC correlates with OS but have not yet been qualified for individual have not yet been qualified for individual patient usepatient use
• Further studies are needed to identify and Further studies are needed to identify and validate predictive markersvalidate predictive markers